Transcenta Holding Limited, a China-based clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced on Wednesday that it has received Orphan Drug Designation from the United States Food and Drug Administration (FDA) for its TST001, an anti-Claudin18.2 monoclonal antibody currently in Phase I clinical trial, to treat patients with gastric cancer or gastroesophageal junction.
According to preclinical and clinical data, the product indicated potent anti-tumour activities in tumour model of gastric cancer or patient of gastric cancer expressing Claudin18.2.
The product is the second Claudin18.2 aimed at antibody therapeutic candidate being developed globally after Zolbetuximab (IMAB362). It is a high-affinity recombinant humanised monoclonal antibody aimed at Claudin18.2 generated by Transcenta's Immune Tolerance Breaking Technology platform.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories